Evelo Biosciences Inc (EVLO) Receives $22.75 Average Price Target from Brokerages

Evelo Biosciences Inc (NASDAQ:EVLO) has earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $22.75.

Separately, Chardan Capital reiterated a “hold” rating and set a $10.00 price objective on shares of Evelo Biosciences in a report on Friday, February 15th.

Shares of NASDAQ EVLO traded up $0.10 during mid-day trading on Friday, reaching $8.30. 10,499 shares of the company’s stock traded hands, compared to its average volume of 31,623. The stock has a market capitalization of $264.52 million and a P/E ratio of -2.99. Evelo Biosciences has a 1-year low of $6.51 and a 1-year high of $16.75. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.43 and a quick ratio of 16.43.

Evelo Biosciences (NASDAQ:EVLO) last issued its quarterly earnings data on Thursday, February 14th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.09. As a group, equities research analysts anticipate that Evelo Biosciences will post -2.48 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC grew its holdings in shares of Evelo Biosciences by 29.5% during the first quarter. Larson Financial Group LLC now owns 7,268 shares of the company’s stock valued at $58,000 after buying an additional 1,655 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Evelo Biosciences by 68.0% during the fourth quarter. Deutsche Bank AG now owns 18,048 shares of the company’s stock valued at $234,000 after buying an additional 7,305 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Evelo Biosciences by 74.8% during the fourth quarter. Geode Capital Management LLC now owns 90,197 shares of the company’s stock valued at $1,173,000 after buying an additional 38,596 shares during the last quarter. FMR LLC grew its holdings in shares of Evelo Biosciences by 1.3% during the fourth quarter. FMR LLC now owns 3,306,007 shares of the company’s stock valued at $43,011,000 after buying an additional 41,100 shares during the last quarter. Finally, Legal & General Group Plc grew its holdings in shares of Evelo Biosciences by 169.8% during the fourth quarter. Legal & General Group Plc now owns 2,142 shares of the company’s stock valued at $28,000 after buying an additional 1,348 shares during the last quarter. Hedge funds and other institutional investors own 85.05% of the company’s stock.

About Evelo Biosciences

Evelo Biosciences, Inc, a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases.

Further Reading: What is the downside to momentum investing?

Analyst Recommendations for Evelo Biosciences (NASDAQ:EVLO)

Receive News & Ratings for Evelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.